Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) is a clinical-stage biopharmaceutical company developing small-molecule medicines for genetically defined rare diseases with high unmet medical need. Its lead candidate, oral pociredir, is designed to increase fetal hemoglobin and is in clinical development for sickle cell… From the company’s description.
In fiscal 2025, Fulcrum Therapeutics, Inc. reported a net loss of $74.88M. Operations used $60.06M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Fulcrum Therapeutics, Inc. does
In the company’s own words
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) is a clinical-stage biopharmaceutical company developing small-molecule medicines for genetically defined rare diseases with high unmet medical need. Its lead candidate, oral pociredir, is designed to increase fetal hemoglobin and is in clinical development for sickle cell disease; the company also sees potential application in some types of beta-thalassemia. Fulcrum has completed dosing in a Phase 1b trial in adults with sickle cell disease and is developing the candidate for patients with rare hematologic disorders. Its discovery approach identifies and validates cellular drug targets that may modulate gene expression, with a primary focus on hematology. The company is also pursuing other research programs, including an EED inhibitor candidate studied in preclinical prostate cancer models, and holds a worldwide exclusive license to CAMP4 Therapeutics’ DBA program. Fulcrum retains rights to pociredir and plans to use a targeted commercial infrastructure for any approved product. It relies on contract manufacturers for production and third parties for clinical trials. Its website is https://www.fulcrumtx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1680581
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Fulcrum Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Fulcrum Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Fulcrum Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Fulcrum Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Fulcrum Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”